08/09/2021 Nota de prensa YSIOS CAPITAL PORTFOLIO COMPANY AM-PHARMA AND KYOWA KIRIN SIGN EXCLUSIVE LICENSE AGREEMENT FOR COMMERCIALIZATION OF LLOFOTASE ALFA IN JAPAN. • AM-Pharma to receive EUR 20 million upfront payment, and EUR 30 million related to milestones prior to regulatory submission, and up to EUR 195 million upon…
31/03/2020 Nota de prensa AM-PHARMA RECIBE €47 MILLONES DE COWEN HEALTHCARE Y DEL EUROPEAN INVESTMENT BANK. • €23m [US$25.5m] equity provided mainly by US-based Cowen Healthcare Investments• €24m [US$26.5m] finance facility provided by the European Investment Bank (EIB)• Increased funding allows for finalization of all Marketing Authorization Application preparation activities• Ysios Capital participated in the…
16/07/2019 Nota de prensa YSIOS CAPITAL PARTICIPA EN LA RONDA DE €116 MILLONES ($133 MILLONES) DE SU PARTICIPADA AM-PHARMA. AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP) today announces that it has…
Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.
ACEPTAR